Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Subcutaneous IgG treatment for primary immunodeficiencies (PI) is particularly well suited for children because it does not require venous access and is mostly free of systemic adverse events (AEs). In a prospective, open-label, multicenter, single-arm, Phase III study, 18 children and five adolesce...

Descripción completa

Detalles Bibliográficos
Autores principales: Borte, Michael, Pac, Malgorzata, Serban, Margit, Gonzalez-Quevedo, Teresa, Grimbacher, Bodo, Jolles, Stephen, Zenker, Othmar, Neufang-Hueber, Jutta, Belohradsky, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221851/
https://www.ncbi.nlm.nih.gov/pubmed/21674136
http://dx.doi.org/10.1007/s10875-011-9557-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221851/
https://www.ncbi.nlm.nih.gov/pubmed/21674136
http://dx.doi.org/10.1007/s10875-011-9557-z

Ejemplares similares